Comparison of two methods of surfactant administration and the effect on dosing-associated hypoxemia.
OBJECTIVE
The purpose of our study was to test the hypothesis that surfactant dosing through a proximal sideport adapter on an endotracheal tube leads to more dosing-associated hypoxemia compared with a method of dosing that uses a double-lumen endotracheal tube.


METHODS
Using adequate sample size to compare significant changes in O2 saturation (power > 0.8, alpha < 0.05) we enrolled 36 infants with respiratory distress syndrome in this randomized trial. A 10% change in O2 saturation was considered clinically significant. Nineteen infants received 38 doses of surfactant through the sideport adapter. Seventeen infants received 31 doses of surfactant through the nonventilation lumen of a double-lumen endotracheal tube. Two main outcome measures were assessed: time-averaged O2 saturation values 30 minutes after dosing and the largest absolute fall in O2 saturation for each patient.


CONCLUSIONS
Time-averaged O2 saturation measures were higher in the proximal sideport group (p = 0.02), but the magnitude of difference was probably not clinically significant. No significant difference was detected between groups when we compared largest absolute drop in O2 saturation. Secondary analyses found no effect of birth weight or dose number (second vs third dose) on either outcome measure.
Nelson
M
M
Department of Pediatrics, University of Michigan Medical Center, Ann Arbor, USA.
Nicks
J J
JJ
Becker
M A
MA
Vrlenich
L A
LA
Bhatt-Mehta
V
V
Schumacher
R E
RE
D000280:Administration, Inhalation; D001724:Birth Weight; D004305:Dose-Response Relationship, Drug; D004453:Echoencephalography; D005260:Female; D005865:Gestational Age; D006801:Humans; D000860:Hypoxia / Q000503:physiopathology*; D007231:Infant, Newborn; D007442:Intubation, Intratracheal; D008297:Male; D010101:Oxygen Consumption / Q000502:physiology; D011446:Prospective Studies; D011663:Pulmonary Surfactants / Q000008:administration & dosage* / Q000627:therapeutic use; D012121:Respiration, Artificial; D012127:Respiratory Distress Syndrome, Newborn / Q000503:physiopathology / Q000628:therapy*; D016896:Treatment Outcome
D011663:Pulmonary Surfactants